FAM19A4基因启动子甲基化检测在宫颈癌及其癌前病变筛查的研究

宫颈癌是最常见的妇科恶性肿瘤之一。目前人乳头瘤病毒(HPV)检测及细胞学检查是宫颈癌及其癌前病变(CCPL)的主要筛查手段。由于上述传统筛查方法,仍然存在对CCPL漏诊的风险,因此寻找有效识别CCPL的特异性分子标志物,具有重要临床意义。对具有序列相似性家族19成员A4(FAM19A4)基因启动子甲基化定量检测,可有效检出CCPL组织,较传统筛查方法有较高特异度,有望成为CCPL筛查的特异性分子标志物。笔者拟就FAM19A4基因启动子甲基化定量检测,在CCPL筛查中应用的最新研究现状进行阐述,旨在为进一步推进CCPL筛查方法的开发,提供思路。     

Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer

Background Despite curative resection, 50%–90% of gastric cancer patients die of disease relapse. Although some clinical trials have indicated that chemotherapy and immunochemotherapy may be effective modalities, more recent studies have not been able to define the standard treatment for advanced gastric cancer. The present study evaluated the effect of adjuvant immunochemotherapy with the use of BCG (bacille Calmette-Guérin) and FAM (5-fluorouracil, adriamycin, mitomycin C) chemotherapy on the survival of patients with locally advanced resectable gastric cancer.Methods A total of 156 patients with stage III or IV gastric cancer who had undergone curative resection were randomly assigned to three treatment groups: BCG + FAM (immunochemotherapy), FAM (chemotherapy), and control (surgery only). Treatment was continued for 2 years or until death. Further postsurgical follow up was carried on for up to 10 years.Results Overall 10-year survival was 47.1% for the immunochemotherapy group (P < 0.037 vs FAM and P < 0.0006 vs control), 30% for the chemotherapy group (vs control, NS), and 15.2% for the control group. In patients with pT2/T3 primary tumors, 10-year survival was 55.3% for BCG + FAM vs 28.2% for FAM (P < 0.01) and 14.6% for the control group (P < 0.00018). BCG + FAM signifi-cantly improved the survival of patients with intestinal-type but not diffuse-type cancer. Immunochemotherapy was well tolerated.Conclusion This study, based on a limited number of patients, indicates that adjuvant immunochemotherapy (BCG + FAM) may prolong the survival of gastric cancer patients after curative gastrectomy; in particular, in patients with pT2/T3 tumors and intestinal-type primary tumors. There was no survival benefit from FAM adjuvant chemotherapy.     

lncRNA FAM95B1在胶质瘤中的表达及其影响LN382细胞增殖和迁移的可能机制

目的:探讨lncRNA FAM95B1对胶质瘤细胞增殖和迁移能力的影响并探究其相关作用机制.方法:选取2018年1月至2020年8月于合肥市第三人民医院行手术治疗的38例胶质瘤患者的胶质瘤组织及癌旁组织标本,利用qPCR检测胶质瘤组织与4种细胞系中FAM95B1的表达水平,以表达最低的胶质瘤LN382细胞为研究对象,转...     

外周血癌细胞中多种肿瘤标记物基因检测预测乳腺癌患者转移和预后的意义

目的：筛选一组可检测乳腺癌循环癌细胞的标记物基因,分析乳腺癌患者相对循环癌细胞数（Lc）与临床病理特征的关联。方法：收集乳腺癌患者142例（乳腺癌组）和正常女性60人（正常对照组）外周血标本。利用CGAP提供的SAGE Genie数据库中数字基因表达演示工具,筛选一组可用于检测乳腺癌循环癌细胞的标记物基因（FAM83A、NPY1R和KRT19）。应用定量巢式PCR方法检测研究对象外周血中标记物基因的表达水平,并通过公式计算患者Lc值。结果：在乳腺癌组患者外周血中肿瘤标记物基因FAM83A、NPY1R和KRT19的表达水平均明显高于正常对照组（P<0.001）。142例乳腺癌患者中有113例（79.6%）至少表达1个肿瘤标记物基因。乳腺癌患者Lc值与其临床分期和远处转移有关联（P<0.001）。Kaplam-Meier生存曲线,Lc值小于2的患者生存时间明显长于Lc值大于2者（P=0.005）。结论：筛选了一组检测乳腺癌外周血循环癌细胞的标记物基因,联合该组基因计算的Lc值与患者临床分期和远处转移有关联,并可辅助判断乳腺癌预后。     

MicroRNA‐7 negatively regulates Toll‐like receptor 4 signaling pathway through FAM177A

Toll‐like receptor (TLR) 4 signalling is critical for innate immunoinflammatory response and widely triggers the development of various types of clinical diseases. MicroRNA‐7 (miR‐7) is well documented to play an important regulatory role in various biological events. However, the exact role of miR‐7 in TLR4 signalling pathway remains to be fully elucidated. In the present study, we found that miR‐7 expression in TLR4 signalling‐activated bone marrow‐derived macrophages (BMDMs) stimulated by LPS was dramatically increased. Importantly, miR‐7 deficiency significantly enhanced the production of related inflammatory cytokines including IL‐1β, IL‐6 and IL‐12, as well as TNF‐α, on LPS‐activated BMDMs, accompanied by elevated transduction of TLR4 signalling including Myd88‐dependent and Myd88‐independent pathways, whereas miR‐7 overexpression significantly decreased the transduction of TLR4 signalling and the production of related inflammatory cytokines. Mechanistically, we identified family with sequence similarity 177, member A (FAM177A) as a novel target molecule of miR‐7. Furthermore, down‐regulation of FAM177A using RNAi could impair the transduction of TLR4 signalling. Finally, down‐regulation of FAM177A also reversed the effect of miR‐7 deficiency on TLR4 signalling transduction and production of related inflammatory cytokines on BMDMs. Therefore, we provide the new evidence that miR‐7 acts as a novel negative fine‐tuner in regulating TLR4 signalling pathways by targeting FAM177A, which might throw light on the basal understanding on the regulatory mechanism of TLR4 signalling and benefit the development of therapeutic strategies against related clinical diseases.     

FGF23 Is Endogenously Phosphorylated in Bone Cells

Levels of serum phosphate are controlled by the peptide hormone FGF23, secreted from bone osteocytes. Elevated levels of circulating FGF23 are a key factor in several hypophosphatemic disorders and play a role in chronic kidney disease. Posttranslational processing of FGF23 includes multi‐site O‐glycosylation, which reduces intracellular cleavage by proprotein convertases. The FGF23 protein also contains four serine phosphorylation consensus sequences (S‐X‐D/E); in this work, we asked whether FGF23 is a substrate for secretory phosphorylation. Both HEK cells as well as IDG‐SW3 cells, an osteocyte model, incorporated radiolabeled orthophosphate into intact FGF23, as well as into the 14‐kDa carboxy‐terminal—but not the 17‐kDa N‐terminal—fragment. Sequential serine‐to‐alanine site‐directed mutagenesis of four kinase consensus sites showed that labeling occurred on three serines within the carboxy‐terminal fragment, Ser180 (adjacent to the cleavage site), Ser207, and Ser212. Liquid chromatography‐coupled mass spectroscopy indicated the presence of phosphate at Ser212 in recombinant R&D mouse FGF23^R179Q, confirming labeling results. A phosphopeptide‐specific antibody was raised against phospho‐Ser212 and exhibited immunoreactivity in osteocytes present in mouse long bone, providing further evidence that FGF23 is naturally phosphorylated in bone. Bone SIBLING proteins are serine‐phosphorylated by the ubiquitous Golgi secretory kinase FAM20C. Cotransfection of HEK and MC3T3 cells with FGF23 and active, but not inactive, FAM20C kinase increased the storage and release of FGF23 in radiolabeling experiments, indicating potential effects of phosphorylation on FGF23 stability. Collectively, these data point to an important role for phosphorylation of FGF23 in bone. © 2014 American Society for Bone and Mineral Research.